Cancer Immunotherapy Comes of Age

Cancer immunotherapy comprises a variety of treatment approaches, incorporating the tremendous specificity of the adaptive immune system (T cells and antibodies) as well as the diverse and potent cytotoxic weaponry of both adaptive and innate immunity. Immunotherapy strategies include antitumor monoclonal antibodies, cancer vaccines, adoptive transfer of ex vivo activated T and natural killer cells, and administration of antibodies or recombinant proteins that either costimulate immune cells or block immune inhibitory pathways (so-called immune checkpoints). Although clear clinical efficacy has been demonstrated with antitumor antibodies since the late 1990s, other immunotherapies had not been shown to be…

• AL
  Abbott Laboratories
• BS
  Bristol-Myers Squibb
• P
  Pfizer
• G
  GlaxoSmithKline
• MR
  Melanoma Research Alliance
• AS
  American Society of Clinical Oncology
• C
  Celgene
• NI
  National Institutes of Health

  Awards: P50 CA97274, CA97274, R01 CA142779, CA142779, P30 CA86862
• G
  Genentech
• TO
  Takeda Oncology